Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiretroviral therapy |
| gptkbp:activeIngredient |
gptkb:abacavir
gptkb:lamivudine gptkb:zidovudine |
| gptkbp:approvalYear |
2000
|
| gptkbp:ATCCode |
gptkb:J05AR04
|
| gptkbp:availableOn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:contraindication |
severe liver impairment
hypersensitivity to abacavir |
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:drugClass |
combination antiretroviral
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trizivir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:ViiV_Healthcare
|
| gptkbp:mechanismOfAction |
protease inhibitor
|
| gptkbp:notRecommendedFor |
children under 12 years
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescribes |
adolescents
adults |
| gptkbp:prescriptionRequired |
yes
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache hypersensitivity reaction |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:abacavir
gptkb:lamivudine |
| gptkbp:bfsLayer |
6
|